Targeting a 2 million-strong patient market in the U.S., startup GT Urological is developing an implantable fake sphincter that can help men control incontinence. The Minneapolis company just raised $5 million, according to a regulatory filing.
The company’s developed an implantable prosthesis called the Phenix Artificial Urinary Sphincter, which treats moderate to severe male stress urinary incontinence – a common issue that follows prostate cancer surgery. It’s under clinical investigation in Europe.
Outside of behavioral modifications and muscle control exercises, there isn’t much available for incontinence treatment. The development process for GT Urological has been slow-going, but would prove to be a unique alternative to a fairly widespread issue in men.
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
Since its launch in 2003, GT Urological’s raised $2.5 million in SBIR funding and $11 million in private equity.